Takeda is buying Ariad Pharmaceuticals in a $5.2 billion Deal
The Japanese pharmaceutical company Takeda is buying Cambridge, Massachussets-based Ariad Pharmaceuticals for $24 a share. The deal is valued at about $5.2 billion and expected to close in February...
Related Articles
- TaskRabbit CEO Steps Down, Making Silicon Valley’s Diversity Outlook Bleak also categorized in BoardNews
- CEOs Are Cutting Their Own Salaries In Response To The Coronavirus also categorized in BoardNews
- Steve Wynn Won't Have to Deal with his Ex-Wife on the Wynn Resorts Board Anymore also written by Portia Crowe
- Here Are The 11 Politicians Who Sit On The Boards Of Public Companies also published in Business Insider
- Breaking News: Standley Is Out As Rite Aid CEO In Shakeup also categorized in BoardNews
- Billionaire Investor Bill Ackman Trims Stake In Chipotle, But Is Still Betting Big On Burritos With 5% Stake also categorized in BoardNews
- CEOs Love Share Buybacks for the Most Obvious Reason in The World also written by Portia Crowe
- Ford Fires CEO Mark Fields; Former Steelcase Chief Jim Hackett To Take Over also categorized in BoardNews
- Billionaire JPMorgan Chief Jamie Dimon Says There’s No Point in Slashing CEO Pay also written by Portia Crowe
- Clash of the Mad Men in $35bn advertising mega-merger also mentions Mergers and Acquisitions
Login to comment.